Snapshot from Sep 14, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory regulatory filing

FDA accepts United Therapeutics ralinepag NDA

Analysis based on 10 articles · First reported Aug 24, 2026 · Last updated Aug 24, 2026

Sentiment
60
Attention
4
Articles
10
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The FDA acceptance of the NDA for ralinepag is a positive regulatory milestone for United Therapeutics, potentially strengthening its position in the PAH treatment market. The news is likely to boost investor sentiment for United Therapeutics, while the FDA's review process will be closely watched by the market.

Biotechnology Pharmaceuticals

United Therapeutics announced that the U.S. United States — Food and Drug Administration has accepted its New Drug Application for ralinepag, an investigational once-daily oral prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. The FDA set a Prescription Drug User Fee Act target action date of June 24, 2027. The filing is based on the phase 3 ADVANCE OUTCOMES study, which met its primary endpoint with a statistically significant 55% reduction in risk of clinical worsening versus placebo in predominantly pre-treated PAH patients. Ralinepag also achieved statistical significance on key secondary endpoints, including reductions in NT-proBNP and improvements in exercise capacity. The safety profile was consistent with known prostacyclin-related adverse events. The data were presented at the American Thoracic Society annual meeting and published in The Lancet. Ralinepag has not yet been approved by the FDA and remains investigational.

stock
United Therapeutics is the sponsor of the NDA and the developer of ralinepag. The FDA acceptance is a key regulatory milestone that could lead to a new product launch and revenue growth.
Importance 100.0 Sentiment 70.0
govactor
The FDA accepted the NDA and set a PDUFA target action date, initiating its review process. The agency's decision will determine whether ralinepag receives marketing approval.
Importance 90.0 Sentiment 0.0
per
As CEO of United Therapeutics, Martine Rothblatt is the public face of the company and commented on the NDA acceptance, highlighting the potential of ralinepag for PAH patients.
Importance 60.0 Sentiment 70.0
ngo
The American Thoracic Society hosted the presentation of the ADVANCE OUTCOMES data at its annual meeting, providing a platform for dissemination of the clinical results.
Importance 30.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.